| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| UNITED STATES | 146.7 | 130.3 | 152.7 | | | |
| Total product and transportation revenue | | | | | | 216.2 |
| U.S. | | | | 213.7 | 232.0 | 190.2 |
| Commercial | | | | 158.3 | 163.2 | 142.5 |
| Other | 25.5 | 17.3 | 18.8 | | | |
| Total revenues | 172.2 | 147.6 | 171.5 | 247.7 | 274.7 | 226.5 |
| Revenue growth [+] | 16.6% | -13.9% | -30.8% | -9.8% | 21.3% | |
| UNITED STATES | 12.6% | -14.7% | | | | |
| U.S. | | | | -7.9% | 22.0% | |
| Commercial | | | | -3.0% | 14.5% | |
| Healthcare | | | | -27.2% | 58.0% | |
| Cost of goods sold | 144.0 | 124.1 | 118.2 | 161.3 | 167.7 | 141.1 |
| Gross profit | 28.2 | 23.5 | 53.3 | 86.4 | 107.0 | 85.5 |
| Gross margin | 16.4% | 15.9% | 31.1% | 34.9% | 39.0% | 37.7% |
| Selling, general and administrative [+] | 27.0 | 31.0 | 28.0 | 61.6 | 69.3 | 74.6 |
| Sales and marketing | 27.0 | 31.0 | 28.0 | 33.9 | 40.6 | 46.2 |
| General and administrative | | | | 27.6 | 28.7 | 28.4 |
| Research and development | | | | 7.8 | 4.2 | 6.3 |
| Other operating expenses | 54.0 | 38.2 | 22.4 | 14.9 | 11.7 | 9.9 |
| EBITDA [+] | -37.6 | -31.3 | 14.6 | 14.4 | 35.5 | 7.5 |
| EBITDA growth | 20.3% | -314.5% | 1.7% | -59.5% | 372.8% | |
| EBITDA margin | -21.9% | -21.2% | 8.5% | 5.8% | 12.9% | 3.3% |
| Depreciation and amortization | 15.1 | 14.5 | 11.7 | 12.2 | 13.7 | 12.9 |
| EBIT [+] | -52.8 | -45.8 | 2.9 | 2.1 | 21.8 | -5.4 |
| EBIT growth | 15.2% | -1688.3% | 36.7% | -90.3% | -506.0% | |
| EBIT margin | -30.6% | -31.0% | 1.7% | 0.9% | 7.9% | -2.4% |
| Non-recurring items [+] | -1.9 | | | 4.6 | 16.1 | 1.1 |
| Asset impairment | -1.9 | | | | 8.7 | |
| Interest expense, net [+] | -0.1 | -0.1 | -0.2 | -0.4 | 0.1 | 0.1 |
| Interest expense | 5.2 | 3.1 | 0.3 | 0.1 | 0.5 | 0.5 |
| Interest income | 0.1 | 0.1 | 0.2 | 0.5 | 0.4 | 0.4 |
| Other income (expense), net [+] | 1.0 | -5.0 | -12.0 | -1.3 | 3.2 | -0.7 |
| Gain (loss) on foreign currency transactions | | | | -1.3 | 3.2 | 0.7 |
| Pre-tax income | -54.9 | -53.9 | -9.2 | -3.4 | 8.8 | -7.3 |
| Income taxes | 0.0 | -0.2 | 2.1 | 1.0 | 3.3 | 0.5 |
| Tax rate | | 0.4% | | | 37.1% | |
| Net income | -55.0 | -53.7 | -11.3 | -4.4 | 5.6 | -7.7 |
| Net margin | -31.9% | -36.4% | -6.6% | -1.8% | 2.0% | -3.4% |
| |
| Basic EPS [+] | ($0.63) | ($0.63) | ($0.13) | ($0.05) | $0.07 | ($0.09) |
| Growth | -0.7% | 373.1% | 157.0% | -179.0% | -172.0% | |
| Diluted EPS [+] | ($0.63) | ($0.63) | ($0.13) | ($0.05) | $0.07 | ($0.09) |
| Growth | -0.7% | 373.1% | 157.0% | -179.5% | -171.6% | |
| |
| Shares outstanding (basic) [+] | 87.7 | 85.0 | 84.7 | 84.7 | 84.5 | 84.7 |
| Growth | 3.1% | 0.4% | 0.0% | 0.2% | -0.2% | |
| Shares outstanding (diluted) [+] | 87.7 | 85.0 | 84.7 | 84.7 | 85.0 | 84.7 |
| Growth | 3.1% | 0.4% | 0.0% | -0.4% | 0.4% | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |